4 result(s) displayed (1 - 4 of 4):

Teva Pharma, bettered by Barr, eyes more M&A (from Corporate Dealmaker)

World No. 1 generic drug maker Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) beat its profit forecast as its $7.46 billion acquisition of Montvale, N.J., rival Barr Pharmaceuticals Inc. is paying off more than expected and it recorded record-breaking sales of Copaxone, a drug used in multiple sclerosis treatment.The Israeli drug company,...

Posted on May 5, 2009 3:12 PM

Whew! Teva gets credit deal for $7.5B Barr purchase (from Corporate Dealmaker)

Companies around the globe are struggling with credit, for example, there's the financing trouble with Hexion Specialty Chemicals Inc.'s $10.5 billion purchase of Huntsman Corp. But Israeli generic drugmaker Teva Pharmaceutical Industries Ltd. lucked out with its $7.46 billion acquisition of Montvale, N.J.'s Barr Pharmaceuticals Inc. A syndicate of...

Posted on October 28, 2008 2:14 PM

Teva Pharmaceuticals: Dealmakers and deal strategy (from Corporate Dealmaker)

With news on Friday that Israel's Teva Pharmaceutical Industries Ltd. was expanding its U.S. operations with yet another acquisition -- this one an $8.9 billion bid to acquire Barr Pharmaceuticals Inc. -- we thought it a good time to look at who's leading dealmaking at the world's largest maker of...

Posted on July 18, 2008 2:56 PM

Nothing generic about returns on Hospira's Mayne Pharma deal (from Corporate Dealmaker)

Hospira Inc. CEO Christopher Begley said in a statement in September 2006 that the $2.1 billion purchase of Australian generic cancer drugs group Mayne Pharma Ltd. would add to Hospira's earnings per share in 2007. Lo and behold, the company just reported a 60% jump in fourth-quarter net income. No...

Posted on February 29, 2008 12:17 PM